New drug IDP-001 takes on advanced cancers in early trial
NCT ID NCT07602842
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study tests a new drug called IDP-001 in people with advanced or spreading solid tumors, including certain lung, head and neck, and other cancers. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 132 adults who have tried other treatments without success will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack Meridian - John Theurer Cancer Center
Edison, New Jersey, 08837, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.